Clinical trial
MK0859 Dose-Ranging Study (0859-003)
NCT00325455 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00325455 |
|---|---|
| Title | MK0859 Dose-Ranging Study (0859-003) |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of MK-0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hypercholesterolemia, Mixed Hyperlipemia |
| Intervention type | Drug |
| Interventions | MK0859 |
| Enrollment | 500 |
| Start date | Jun 1, 2006 |
| Primary completion | Feb 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | May 12, 2006 |
| Last update posted | Mar 2, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: